A paradigm for Africa-centric vaccine development in Equatorial Guinea (Publications)
The Equatorial Guinea Malaria Vaccine Initiative (EGMVI) highlights how long-term African government and international energy industry investment, plus novel partnerships, can enable clinical development
Synthesis of szentiamide, a depsipeptide from entomopathogenic <em>Xenorhabdus szentirmaii</em> with activity against <em>Plasmodium falciparum</em> (Publications)
on of a notable activity against insect cells and Plasmodium falciparum, the causative agent of malaria
A paradigm for Africa-centric vaccine development in Equatorial Guinea (Publications)
The Equatorial Guinea Malaria Vaccine Initiative (EGMVI) highlights how long-term African government and international energy industry investment, plus novel partnerships, can enable clinical development
Synthesis of szentiamide, a depsipeptide from entomopathogenic <em>Xenorhabdus szentirmaii</em> with activity against <em>Plasmodium falciparum</em> (Publications)
on of a notable activity against insect cells and Plasmodium falciparum, the causative agent of malaria
Inference for entomological semi-field experiments: fitting a mathematical model assessing personal and community protection of vector-control... (Publications)
and metofluthrin spatial repellents, as well as combined interventions for Plasmodium falciparum malaria in Anopleles minimus. Overall, all interventions had both personal and community effects, preventing [...] than just reduction in biting, to be parameterised and highlights the tools assessed as promising malaria interventions.
Prospective risk of morbidity in relation to multiplicity of infection with <em>Plasmodium falciparum </em>in Sao Tomé (Publications)
confounding by patterns of health service usage is an alternative explanation. The incidence of clinical malaria episodes was only a little higher in children than in adults. This weak age-dependence in clinical [...] a consequence of a cohort effect resulting from resurgence of the disease after the breakdown of malaria control programs in the 1980s.
A comparative study of the efficacies of chloroquine and a pyrimethamine-dapsone combination in clearing <em>Plasmodium falciparum</em> parasitaemia... (Publications)
100 mg dapsone for children 10 or more years old) as a single dose. Children were followed-up for malaria parasitaemia at days 2, 7 and 14 after screening, randomization and treatment. The slide positivity [...] pyrimethamine-dapsone appears to be a better choice than chloroquine as a chemoprophylactic regimen for malaria in this area. Although they need to be confirmed in a larger study, these results may be of interest
Antibodies elicited by a virosomally formulated <em>Plasmodium falciparum</em> serine repeat antigen-5 derived peptide detect the processed 47kDa... (Publications)
Serine repeat antigen-5 (SERA5) is a candidate antigen for inclusion into a malaria subunit vaccine. During merozoite release and reinvasion the 120kDa SERA5 precursor protein (P120) is processed, and [...] peptide FB-23 is suitable for use in humans and represents a candidate component for a multi-valent malaria subunit vaccine targeting both sporozoites and blood stage parasites
Activity refinement of aryl amino acetamides that target the <em>P. falciparum</em> STAR-related lipid transfer 1 protein (Publications)
Malaria is a devastating disease that causes significant morbidity worldwide. The development of new antimalarial chemotypes is urgently needed because of the emergence of resistance to frontline therapies [...] a useful tool for further investigating the druggability of PfSTART1 across the lifecycle of the malaria parasite.
The <em>Plasmodium </em>lactate/H+ transporter PfFNT is essential and druggable <em>in vivo</em> (Publications)
Malaria parasites in the blood stage express a single transmembrane transport protein for the release of the glycolytic end product l-lactate/H(+) from the cell. This transporter is a member of the strictly [...] ty of the PfFNT target on a genetic level, and established its in vivo druggability using mouse malaria models. We found that, besides a previously identified PfFNT G107S resistance mutation, selection